NEW YORK – Immunotherapy developer Advaxis and sequencing firm Personalis said today that they have entered an extended collaboration agreement, under which they are using Personalis' ImmunoID NeXT Platform for biomarker discovery in Advaxis' ongoing Phase I/II program advancing the investigational ADXS-503 alone and in combination with pembrolizumab for patients with non-small cell lung cancer.